DiaSorin SpA (DIA) - Financial and Strategic SWOT Analysis Review

April 2021 | 48 pages | ID: D561ADA2534EN
GlobalData

Abstracts

DiaSorin SpA (DIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

DiaSorin SpA (DiaSorin) is a medical diagnostics company that develops, manufactures, and markets in vitro diagnostics reagent kits and systems. The company develops reagent kits based on Enzyme Linked Immunosorbent Assays (ELISA) and Chemiluminescence (CLIA) techniques, to enable automatic diagnostic investigation. The company’s immunodiagnostic and molecular diagnostics products find application in the diagnosis of infectious diseases, bone and mineral disorders, endocrinology, hypertension, oncology, gastrointestinal infections, autoimmune disorders, and neurological and cardiac diseases. DiaSorin markets its products through direct sales force and distributors. It has operations in North America, South America, South Africa, Europe, the Middle East, Africa and Asia. DiaSorin is headquartered in Saluggia, Piemonte, Italy.

DiaSorin SpA Key Recent Developments

Mar 31,2020: AdvaMed: COVID-19 test availability rapidly scales up
Mar 20,2020: Diagnostics Manufacturers ramping up COVID-19 tests to combat pandemic

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

DiaSorin SpA - Key Facts
DiaSorin SpA - Key Employees
DiaSorin SpA - Key Employee Biographies
DiaSorin SpA - Major Products and Services
DiaSorin SpA - History
DiaSorin SpA - Company Statement
DiaSorin SpA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
DiaSorin SpA - Business Description
Product Category: CLIA Tests
Overview
Performance
Product Category: ELISA Tests
Overview
Performance
Product Category: Instruments Sales and Other Revenue
Performance
Product Category: Molecular Tests
Overview
Performance
Geographical Segment: Asia Pacific
Performance
Geographical Segment: Europe and Africa
Performance
Geographical Segment: Latin America
Performance
Geographical Segment: USA and Canada
Performance
R&D Overview
DiaSorin SpA - Corporate Strategy
DiaSorin SpA - SWOT Analysis
SWOT Analysis - Overview
DiaSorin SpA - Strengths
DiaSorin SpA - Weaknesses
DiaSorin SpA - Opportunities
DiaSorin SpA - Threats
DiaSorin SpA - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

DiaSorin SpA, Medical Equipment, Deals By Year, 2015 to YTD 2021
DiaSorin SpA, Medical Equipment, Deals By Type, 2015 to YTD 2021
DiaSorin SpA, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 31, 2020: AdvaMed: COVID-19 test availability rapidly scales up
Mar 20, 2020: Diagnostics Manufacturers ramping up COVID-19 tests to combat pandemic

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

DiaSorin SpA, Key Facts
DiaSorin SpA, Key Employees
DiaSorin SpA, Key Employee Biographies
DiaSorin SpA, Major Products and Services
DiaSorin SpA, History
DiaSorin SpA, Other Locations
DiaSorin SpA, Subsidiaries
DiaSorin SpA, Key Competitors
DiaSorin SpA, Ratios based on current share price
DiaSorin SpA, Annual Ratios
DiaSorin SpA, Annual Ratios (Cont...1)
DiaSorin SpA, Annual Ratios (Cont...2)
DiaSorin SpA, Interim Ratios
DiaSorin SpA, Medical Equipment, Deals By Year, 2015 to YTD 2021
DiaSorin SpA, Medical Equipment, Deals By Type, 2015 to YTD 2021
DiaSorin SpA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

DiaSorin SpA, Performance Chart (2016 - 2020)
DiaSorin SpA, Ratio Charts
DiaSorin SpA, Medical Equipment, Deals By Year, 2015 to YTD 2021
DiaSorin SpA, Medical Equipment, Deals by Type, 2015 to YTD 2021